Cusp Overlap for Higher CoreValve Implantation

Implant depth greater than the length of the membranous septum is an independent predictor of permanent pacemaker implantation. Valve implantation 3 to 5 mm below the aortic annulus in a projection coaxial to the device is recommended. The problem is this is rarely in the annular plane of the valve.

Cirugía para mejorar la sobrevida en insuficiencia tricuspidea aislada

Ideal annular plane projection is normally suggested by CT. For CoreValves, correction of parallax was achieved by adding right anterior oblique caudal angulation, which preserves the anatomic annular plane of the native valve and produces an overlap of right and left coronary cusps (cusp overlap).

This differs from manufacturer recommendation to use left anterior oblique angulation. This produces a shallower apparent device depth of 1 to 2 mm.

This technique could enable higher implantation, making the self-expandable valve more competitive in terms of conduction, vs balloon expandable valves. 

The risk of excessively higher implantation with this technique might increase paravalvular regurgitation, or even embolization.  


Read also: Should Total Occlusion Influence on Revascularization Strategy?


Small observational studies on cusp overlap have shown permanent pacemaker implantation rate lower than 5% for CoreValve and no significant increase in leak or device embolization. 

Implantation 3 to 5 mm below the aortic annulus, using a radiographic projection chosen for both the valve and the device can help improve permanent pacemaker implantation rate. 

This should be confirmed by multicenter registries, with special attention to low-risk population. 

CIRCINTERVENTIONS-120-009258free

Original Title Low Rates of Permanent Pacing Are Observed Following Self-Expanding Transcatheter Aortic Valve Replacement Using an Annular Plane Projection for Deployment.

Reference: Anthony D. Pisaniello et al. Circ Cardiovasc Interv. 2021;14:e009258. DOI: 10.1161/CIRCINTERVENTIONS.120.009258.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...